Skip to main content
. Author manuscript; available in PMC: 2021 Apr 5.
Published in final edited form as: Clin Cancer Res. 2019 Apr 19;25(14):4264–4270. doi: 10.1158/1078-0432.CCR-19-0361

Table 1.

Baseline Characteristics

Total Cohort n=297 Number with Available Data
Age, median (range) 67 (37–91) 297
Male, % 68.0% 297
Baseline renal dysfunction (creatinine clearance < 80 mL/min), % 46.8% 188
R/R, % 95.6% 297
Unmutated IGHV, % 84% 94
del(17p), % 45% 278
Prior lines of therapy, median (range) 3 (0–15) 297
Prior ibrutinib, % 80% 281
Venetoclax monotherapy, % 80% 296
TLS Risk
 Low, % 40% 295
 Intermediate, % 31.9% 295
 High, % 28.1% 295
TLS Rate 8% 296